LDLR and neoplasm: As LDLR interacts with the CD8+ T-cell receptor complex and promotes TCR recycling and signaling, PCSK9 binding to LDLR reduces TCR recycling, signaling and cytotoxic T-lymphocyte anti-tumor activity [226].